Aarti Pharmalabs Ltd
Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]
- Market Cap ₹ 8,317 Cr.
- Current Price ₹ 918
- High / Low ₹ 950 / 521
- Stock P/E 32.3
- Book Value ₹ 203
- Dividend Yield 0.32 %
- ROCE 17.4 %
- ROE 14.8 %
- Face Value ₹ 5.00
Pros
- Company has delivered good profit growth of 564% CAGR over last 5 years
Cons
- Promoter holding has decreased over last quarter: -0.37%
- Company has a low return on equity of 13.6% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
0 | 0 | 941 | 1,511 | 1,502 | 1,771 | |
0 | 0 | 761 | 1,203 | 1,156 | 1,345 | |
Operating Profit | -0 | 0 | 180 | 308 | 346 | 427 |
OPM % | 19% | 20% | 23% | 24% | ||
0 | 0 | 3 | 1 | 11 | 14 | |
Interest | 0 | 0 | 11 | 20 | 17 | 26 |
Depreciation | 0 | 0 | 37 | 56 | 66 | 79 |
Profit before tax | -0 | 0 | 134 | 233 | 275 | 336 |
Tax % | 0% | 20% | 26% | 27% | 23% | |
-0 | 0 | 107 | 172 | 201 | 257 | |
EPS in Rs | 18.95 | 22.14 | 28.39 | |||
Dividend Payout % | 0% | 0% | 11% | 14% | 18% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 23% |
TTM: | 18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 564% |
3 Years: | 34% |
TTM: | 28% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 52% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 14% |
Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Equity Capital | 0.25 | 0.25 | 0.25 | 45 | 45 | 45 |
Reserves | -0 | -0 | 1,284 | 1,393 | 1,576 | 1,799 |
0 | 0 | 327 | 208 | 272 | 411 | |
0 | 0 | 215 | 330 | 404 | 468 | |
Total Liabilities | 0 | 0 | 1,827 | 1,976 | 2,297 | 2,724 |
0 | 0 | 701 | 848 | 953 | 1,127 | |
CWIP | 0 | 0 | 187 | 102 | 137 | 301 |
Investments | 0 | 0 | 40 | 55 | 62 | 57 |
0 | 0 | 898 | 971 | 1,145 | 1,239 | |
Total Assets | 0 | 0 | 1,827 | 1,976 | 2,297 | 2,724 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
-0 | 0 | -65 | 216 | 184 | 340 | |
0 | 0 | -134 | -116 | -184 | -420 | |
0 | 0 | 255 | -157 | 4 | 79 | |
Net Cash Flow | 0 | 0 | 56 | -56 | 4 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|
Debtor Days | 118 | 90 | 109 | 114 | ||
Inventory Days | 359 | 240 | 283 | 226 | ||
Days Payable | 106 | 95 | 124 | 103 | ||
Cash Conversion Cycle | 371 | 235 | 268 | 236 | ||
Working Capital Days | 263 | 168 | 197 | 182 | ||
ROCE % | 0% | 18% | 16% | 16% | 17% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
20 May - Annual Secretarial Compliance Report for FY ended March 31, 2025; no non-compliance noted.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
16 May - Q4 FY25: Revenue Rs. 564 Cr (+11%), FY25 Rs. 2,113 Cr (+14%); EBITDA Rs. 146 Cr (+24%), PAT Rs. 88 Cr (+35%); Rs. 400-450 Cr …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
12 May - Audio recording of Q4 and FY25 earnings call uploaded on company website.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 12 May
- Announcement under Regulation 30 (LODR)-Investor Presentation 12 May
Annual reports
Concalls
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT REC
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT REC
-
Aug 2024TranscriptNotesPPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
Business Overview:[1]
Aarti Pharmalabs Limited (APL) formerly known as Aarti Organics was established in 1984 as a WOS of Aarti Industries Limited. Got demerged in Oct,22 into a separately listed entity.
Co. is an internationally recognized manufacturer of generic API & Intermediates, Xanthine derivatives and offers CDMO/CMO services. Company has 6 manufacturing plants and 3 R&D centres.